Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases.
The last earnings update was 40 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Inovio Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Inovio Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Inovio Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Inovio Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Inovio Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Inovio Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Inovio Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Inovio Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Inovio Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Inovio Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. J. Joseph Kim, Ph.D has been the Chief Executive Officer of Inovio Pharmaceuticals, Inc. (alternate name: Inovio Biomedical Corp) since June 1, 2009 and has been its President since October 6, 2009. Dr. Kim co-founded ADViSYS Inc., a subsidiary of Viral Genomix in 1997 and served as its Chief Executive Officer and President. He co-founded VGX Pharmaceuticals, LLC (Formerly Viral Genomix, Inc) in 2000 and served as its Chief Executive Officer and President from 2000 to June 1, 2009. Dr. Kim is a veteran of the biopharmaceutical industry. Dr. Kim joined VGX Pharmaceuticals from Merck & Co. He has over 10 years of experience in the field of biopharmaceuticals, with a focus on drug and vaccine development. He serves as the Chairman of VGX Animal Health, Inc. He has been Director of Inovio Biomedical Corp since June 1, 2009. He served as Director of ADViSYS Inc. Dr. Kim served as Director of VGX Pharmaceuticals, LLC from 2000 to June 1, 2009. In 2002, Dr. Kim has been named one of the world’s top 100 young innovators by Technology Review magazine. The “TR100”, as this group is called was chosen by a very distinguished Panel of Judges (which includes 2 Nobel Prize Laureates). Recently, he has been selected for the “40 under 40” by the Philadelphia Business Journal as one of the 40 most dynamic professionals who are under 40 years of age in the region. Dr. Kim was also selected on the list of the “50 Most Influential Men“ in the October 2003 and in the October 2006 “Power Issue“ of Details Magazine. He was featured in the “Who's Next 2005“ issue of Newsweek International. In 2006, Dr. Kim has been named a Young Global Leader by the Forum of Young Global Leaders, an affiliate of the World Economic Forum. He was among 175 leading executives, public figures and intellectuals under the age of 40 from 50 countries. Dr. Kim has been a Director at Inovio Pharmaceuticals, Inc. since June 1, 2009. Dr. Kim is a veteran of the biopharmaceutical industry. He was trained in economics, engineering and biological sciences at MIT where he was a Robert C. Byrd Federal Honors Scholar. Dr. Kim holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.
J.'s compensation has been consistent with company performance over the past year.
J.'s remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Inovio Pharmaceuticals management team is less than 2 years, this suggests a new team.
CEO, President & Director
Chief Financial Officer
COO & Executive VP
Chief Scientific Officer & Executive VP
Director of Investor Relations
Senior Vice President of Quality Assurance
Senior Vice President of Clinical Operations & Global Integration
Senior Vice President of Regulatory Affairs
Senior Vice President of Engineering Development
Senior Vice President of Research & Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Inovio Pharmaceuticals board of directors is about average.
Board of Directors
Chairman of Board of Directors
CEO, President & Director
Chairman of the Scientific Advisory Board & Director
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.